Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05162183 · ClinicalTrials.gov registry record
Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 3,474
- Enrollment target
NCT05162183: Completed study, sponsored by Brigham and Women's Hospital.
NCT05162183 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 3,474 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05162183 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 3,474 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Claims-based algorithm: relative hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up)
Interventions
- DRUG Liraglutide
- DRUG Glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,474 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2021-09-01 |
What the finished NCT05162183 record still lists
NCT05162183 is an observational study that tracks outcomes without assigning an intervention. Its 3,474 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Liraglutide is the first listed.
NCT05162183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05162183 about?
NCT05162183 is a clinical study titled "Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT05162183?
This trial is currently completed. The enrollment target is 3,474 participants. The study started on 2019-09-01. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT05162183?
The interventions under investigation include: Liraglutide (DRUG), Glimepiride (DRUG).
Who is sponsoring clinical trial NCT05162183?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI